Maeda O, Saiki S, Kinouchi T, Kuroda M, Miki T, Usami M, Kotake T
Department of Urology, Center for Adult Diseases, Osaka.
Hinyokika Kiyo. 1991 Feb;37(2):135-9.
At the Center for Adult Diseases, Osaka, between 1961 and 1987, 28 cases (1.8%) of incidental prostatic adenocarcinoma were detected by transurethral or subcapsular prostatectomy for clinically benign prostatic hypertrophy (1388 cases) and cysto-prostatectomy for urinary bladder carcinoma (156). Nine (32%) and 19 (68%) cases were in stages A1 and A2, respectively. Of the 19 A2 cases, 9 were well, 9 were moderately and 1 was poorly differentiated adenocarcinoma. Five of the A2 and 1 of the A1 progressed into clinical carcinoma, but none of these patients died of the cancer. Four of these 5 A2 patients had received no treatment postoperatively and one received castration. The intervals from diagnosis to progression ranged from 11 to 78 months. The survival rates at 5 and 10 years with A1 were 75% and 75%, and those with A2 were 80% and 37%. We conclude that the patients in stage A2 should be treated because stage A2 tumors, especially those with no treatment, progress at a higher frequency than stage A1 tumors.
1961年至1987年期间,在大阪成人疾病中心,经尿道或包膜下前列腺切除术治疗临床诊断为良性前列腺增生(1388例)以及膀胱肿瘤行膀胱前列腺切除术(156例)时,偶然发现28例(1.8%)前列腺腺癌。其中9例(32%)为A1期,19例(68%)为A2期。在19例A2期病例中,9例为高分化腺癌,9例为中分化腺癌,1例为低分化腺癌。5例A2期和1例A1期进展为临床癌,但这些患者均未死于癌症。5例A2期患者中,4例术后未接受治疗,1例接受了去势治疗。从诊断到进展的时间间隔为11至78个月。A1期患者5年和10年生存率分别为75%和75%,A2期患者分别为80%和37%。我们得出结论,A2期患者应接受治疗,因为A2期肿瘤,尤其是那些未接受治疗的肿瘤,进展频率高于A1期肿瘤。